Annual report pursuant to Section 13 and 15(d)

Cover Page

Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Feb. 27, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-36421    
Entity Registrant Name Aurinia Pharmaceuticals Inc.    
Entity Incorporation, State or Country Code Z4    
Entity Address, Address Line One #1203-4464 Markham Street    
Entity Tax Identification Number 98-1231763    
Entity Address, City or Town Victoria    
Entity Address, State or Province BC    
Entity Address, Postal Zip Code V8Z 7X8    
City Area Code (250)    
Local Phone Number 708-4272    
Title of 12(b) Security Common shares, no par value    
Trading Symbol AUPH    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 1,420
Entity Common Stock, Shares Outstanding   142,576,689  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after registrant’s fiscal year end of December 31, 2022 are incorporated by reference into Part III of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001600620